Meiji Seika Pharma Co., Ltd. has announced the initiation of a Phase I clinical trial for ME3241, an innovative anti-PD-1 agonist monoclonal antibody developed through a research collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). The early-stage clinical study has begun in Australia and represents a significant step toward developing new treatments for autoimmune and inflammatory diseases driven by excessive immune responses.
Phase I Trial to Assess Safety and Biological Activity
The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study aimed at evaluating the safety, tolerability, and biological behavior of ME3241 in humans. Researchers will analyze how the drug behaves in the body following both single and multiple doses, including its pharmacokinetics (how the drug is absorbed, distributed, metabolized, and eliminated) and pharmacodynamics (how the drug affects the body’s immune system).
This early-stage study is a crucial milestone in determining whether ME3241 can safely move forward to larger trials. The study has been registered on ClinicalTrials.gov NCT07422207, reflecting transparency in its research process and allowing the global scientific community to track its progress.
Discovery Through Collaborative Research
ME3241 emerged from a collaborative research initiative between Meiji Seika Pharma and FBRI led by Tasuku Honjo, professor emeritus at Kyoto University and Program Director at FBRI. Honjo is internationally recognized for his groundbreaking research on immune checkpoint pathways, particularly the PD-1 (programmed cell death protein 1) mechanism that regulates immune responses.
PD-1 is a receptor found on activated T cells and other immune cells. Under normal circumstances, this receptor acts as a regulatory checkpoint that helps prevent excessive immune activity by suppressing immune responses when necessary. While this mechanism is essential for maintaining immune balance, manipulating PD-1 pathways has become a major focus of modern biomedical research.
Through their joint work, scientists at Meiji Seika Pharma and FBRI identified specific conditions under which stimulating PD-1 using specialized antibodies could trigger immunosuppression. Their findings were published in the scientific journal Science Immunology on January 13, 2023, highlighting the novelty and scientific importance of the discovery.
A New Therapeutic Approach Opposite to Cancer Immunotherapy
What makes ME3241 particularly notable is that it works in a manner opposite to widely used cancer immunotherapies. Many cancer treatments today rely on PD-1 inhibitor or antagonist antibodies, which block PD-1 activity in order to boost the immune system’s ability to attack tumors.
In contrast, ME3241 is designed as a PD-1 agonist antibody, meaning it activates the PD-1 pathway. By stimulating PD-1 signaling, the therapy aims to reduce excessive immune activity, which is a key factor in autoimmune diseases such as rheumatoid arthritis, lupus, and other inflammatory disorders.
Researchers believe that ME3241’s enhanced PD-1 agonist activity could help restore immune balance and potentially provide a new treatment strategy for patients whose immune systems mistakenly attack their own tissues.
Potential Impact for Autoimmune Disease Treatment
Autoimmune diseases occur when the immune system becomes overactive and targets healthy cells and organs. Current treatments often involve broad immunosuppressive drugs that can reduce inflammation but may also weaken the body’s ability to fight infections.
By targeting the PD-1 pathway more precisely, ME3241 could offer a more targeted immunomodulatory therapy. If successful, it may help control disease activity while minimizing the side effects associated with conventional immunosuppressive medications.
Insights from Tasuku Honjo
Commenting on the milestone, Professor Tasuku Honjo emphasized the importance of reaching the clinical stage. According to Honjo, initiating a Phase I clinical trial of a therapy based on PD-1 agonist antibodies represents a major advancement in translating fundamental immunology research into practical treatments for human disease.
Honjo explained that the concept originated from basic research conducted shortly after he began his leadership role at FBRI. After producing strong results in preclinical animal studies, the research team was able to move forward into human trials.
He also noted that if the Phase I study confirms safety, the program could proceed to Phase II trials to assess efficacy, followed by Phase III studies aimed at large-scale clinical validation. Such progress would bring the therapy closer to real-world medical use.
Honjo expressed enthusiasm about the trial’s launch, describing it as an important step toward realizing the long-term vision of the Kobe Biomedical Innovation Cluster, a research ecosystem dedicated to advancing biomedical science and healthcare innovation.
Commitment from Meiji Seika Pharma
Takeshi Naruse, Senior Managing Executive Officer and Head of Research and Development at Meiji Seika Pharma, also highlighted the importance of the collaboration with Professor Honjo and his team. Naruse explained that the company has been actively pursuing research in inflammatory diseases, a therapeutic area closely related to its longstanding focus on infectious disease research.
He noted that ME3241 represents a unique therapeutic candidate developed through a strong foundation of scientific discovery and collaboration. The initiation of the Phase I clinical trial marks the transition from laboratory research to human clinical evaluation.
Naruse reaffirmed Meiji Seika Pharma’s commitment to accelerating the development of ME3241 and working toward delivering the therapy to patients suffering from autoimmune diseases as quickly as possible.
Source Link :https://www.businesswire.com/
